ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements
Asston Pharmaceuticals Ltd submitted its quarterly shareholding pattern disclosure, detailing the shareholding status of promoters and public shareholders for the period ended March 2026.
Asston Pharmaceuticals has submitted its 7th Annual Report for the financial year 2025-26. The report provides a comprehensive overview of the company's annual financial performance.
Asston Pharmaceuticals Limited announced its Annual General Meeting scheduled for September 29, 2026. The agenda includes adopting financial statements, appointing auditors, and revising remuneration for key managerial personnel.
Asston Pharmaceuticals allotted 24,10,431 equity shares at Rs. 115 per share via preferential allotment, raising Rs. 27.72 Crore. This increases the company's paid-up equity share capital.
Asston Pharmaceuticals announced the outcome of its board meeting, including auditor appointments, director re-appointment, and upcoming AGM scheduling. The board also proposed remuneration increases for directors.
Asston Pharmaceuticals Ltd reported revenue from operations of ₹10.1 Cr (+11.0% YoY) and net profit of ₹0.5 Cr (-75.0% YoY) for H2 FY26.